Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056)

PHASE2CompletedINTERVENTIONAL

Enrollment

566

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions

Hepatitis BHepatocellular Carcinoma

Interventions

BIOLOGICAL

Comparator: RECOMBIVAX HB™

RECOMBIVAX HB™ 3 x 5-mcg regimen administered via intramuscular injection.

BIOLOGICAL

Comparator: Modified process Hepatitis B Vaccine

Modified Process Hepatitis B 3 x 5-mcg regimen administered via intramuscular injection.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00322361 - Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056) | Biotech Hunter | Biotech Hunter